X
Xencor Inc (XNCR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$35.40
-1.69 (-4.56%)
Market Cap: $2.78B
Last updated: Nov 17, 2026 at 11:06 AM ET
Xencor Inc (XNCR) Valuation Multiples
Xencor (XNCR) trades at 13.5x sales and 4.8x book value. Its P/S of 13.5x is above its 5-year median of 8.1x. Its forward P/E is 68.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 68.0x |
| Price to sales | 13.5x |
| Price to book | 4.8x |
| PEG | N/A |
| FCF yield | -6.5% |
Historical Medians
Against its 10-year medians, its P/S is 16.4% above 11.6x and its P/B is 65.5% above 2.9x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 13.5x | 8.1x | 11.6x |
| P/B | 4.8x | 2.1x | 2.9x |
Valuation History
Over the 3 of the 10 year ends shown that have a P/E, its P/E ranged from 29.7x in 2021 to 76.4x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $15.31 | N/A | 9.0x | 1.8x |
| 2024 | $22.98 | N/A | 13.9x | 2.5x |
| 2023 | $21.23 | N/A | 7.3x | 2.0x |
| 2022 | $26.04 | N/A | 9.4x | 2.1x |
| 2021 | $40.12 | 29.7x | 8.7x | 3.3x |
| 2020 | $43.63 | N/A | 20.4x | 4.4x |
| 2019 | $34.39 | 76.4x | 12.4x | 3.3x |
| 2018 | $36.16 | N/A | 49.9x | 3.9x |
| 2017 | $21.92 | N/A | 22.2x | 3.7x |
| 2016 | $26.32 | 47.0x | 10.0x | 3.6x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About XNCR
What is XNCR's forward P/E ratio?
Xencor has a forward P/E ratio of 68.0x.
Is XNCR stock overvalued?
GNG's valuation label for XNCR is Overvalued.
What is XNCR's price to sales ratio?
Xencor has a price to sales ratio of 13.5x.
XNCR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors